Todays Report: Today, Marble Harbor Investment Counsel LLC Cuts Stake in Teva Pharmaceutical Industries Ltd. (TEVA)

Today, Marble Harbor Investment Counsel LLC Cuts Stake in Teva Pharmaceutical Industries Ltd. (TEVA)

Marble Harbor Investment Counsel LLC lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.4% during the third quarter, Holdings Channel reports. The institutional investor owned 24,975 shares of the company’s stock after selling 3,550 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in Teva Pharmaceutical Industries were worth $1,149,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in TEVA. Sharkey Howes & Javer increased its stake in shares of Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock worth $101,000 after buying an additional 358 shares during the last quarter. Hudock Capital Group LLC increased its stake in Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock worth $103,000 after buying an additional 564 shares during the last quarter. WFG Advisors LP increased its stake in Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares during the last quarter. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock worth $107,000 after buying an additional 64 shares during the last quarter. Finally, Washington Trust Bank increased its stake in Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock worth $103,000 after buying an additional 58 shares during the last quarter. 63.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded up 0.26% during midday trading on Friday, hitting $38.21. 2,320,788 shares of the stock were exchanged. The stock’s 50 day moving average is $41.87 and its 200 day moving average is $49.35. The firm has a market cap of $38.78 billion, a P/E ratio of 22.23 and a beta of 0.73. Teva Pharmaceutical Industries Ltd. has a 12-month low of $37.12 and a 12-month high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a net margin of 8.81% and a return on equity of 16.75%. The company had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the prior year, the business posted $1.35 EPS. Teva Pharmaceutical Industries’s quarterly revenue was up 15.3% on a year-over-year basis. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post $5.14 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, December 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is 50.58%.

A number of research firms have recently issued reports on TEVA. RBC Capital Markets set a $71.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Sunday, September 11th. Bank of America Corp. set a $72.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Saturday, October 1st. Deutsche Bank AG set a $68.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Saturday, October 15th. Piper Jaffray Cos. reiterated a “neutral” rating and set a $57.00 price target (up from $55.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, August 8th. Finally, Vetr upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $58.99 price target for the company in a research report on Wednesday, August 10th. Thirteen analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $60.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Related posts

Leave a Comment